LivingGLP1
Study S000654

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Clinical Trial to Evaluate the Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects

ClinicalTrials.gov record

Registration

Registration
NCT06921486
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2; PHASE3
Masking
QUADRUPLE
Status
ACTIVE_NOT_RECRUITING
Enrollment
1003
Start
2025-03-31
Primary completion
2026-08-31
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions
Obesity and Overweight
Interventions
DRUG:Phase IIb：Efsubaglutide Alfa 5 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 10 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 20 mg QW; DRUG:Phase IIb：Efsubaglutide Alfa 20 mg Q2W; DRUG:Phase IIb：Placebo; DRUG:Phase III：Recommended Phase 3 Dose High Dose; DRUG:Phase III：Recommended Phase 3 Dose Low Dose; DRUG:Phase III：Placebo
Results posted
FALSE
Individual participant data sharing
NO
Secondary identifiers
OTHER:YN011-W202; OTHER:YN011-W303

Registered primary outcomes

  • Percentage change in body weight from baseline [Phase IIb (18 weeks) , Phase III (30 weeks)]
  • Proportion of subjects with ≥5% reduction in body weight from baseline [Phase III (30 weeks)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R00373912636-P: Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study
YUQIAN BAO, Diabetes
2026Randomized trialDOIcites ClinicalTrials.gov:NCT06921486